‘ Is life worth living? It all depends on the liver’ (American philosopher William James [1842—1910]) Non-alcoholic fatty liver disease (NAFLD) is currently the most frequent global liver disease.1 ...

Background Endoscopic procedures are a notable source of medical waste, contributing significantly to environmental pollution ...

Data from experimental studies have demonstrated that marine omega-3 polyunsaturated fatty acids (O3FAs) have anti-inflammatory and anticancer properties. In the last decade, large-scale randomised ...

Background Chronic inflammation and elevated reactive oxygen species are key contributors to hepatocellular carcinoma (HCC) ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is ...

A high adenoma detection rate (ADR) is vital for effective colorectal cancer (CRC) screening, but evidence suggests limited additional benefit beyond a certain threshold. In a pooled analysis of five ...

Objective IBD therapies and treatments are evolving to deeper levels of remission. Molecular measures of disease may augment current endpoints including the potential for less invasive assessments.

We have recently reported the immune-promoting effects of butyrate in microsatellite stable (MSS) colorectal cancer (CRC) based on mouse models.1 However, its potential application in human CRC and ...

The debate on the necessity of follow-up biopsy in coeliac disease has been ongoing for decades. The follow-up biopsy was dropped largely to reduce the burden of diagnosis and management in children.

Transcription factors of the family p53 have emerged as an important set of tumour suppressors, able to regulate various cell functions like cell cycle arrest, differentiation, DNA repair, apoptosis ...

Objective Extracellular matrix protein 1 (ECM1) serves as a gatekeeper of hepatic fibrosis by maintaining transforming growth factor-β1 (TGF-β1) in its latent form. ECM1 knockout (KO) causes latent (L ...

Objective We evaluated the histamine 1 receptor antagonist ebastine as a potential treatment for patients with non-constipated irritable bowel syndrome (IBS) in a randomised, placebo-controlled phase ...